Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.
from Front page feed https://ift.tt/2z5v0KG
from Front page feed https://ift.tt/2z5v0KG
Comments
Post a Comment